Sigma Healthcare (Sigma Healthcare) Interest Expense : $-11 Mil (TTM As of Jan. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sigma Healthcare Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sigma Healthcare's interest expense for the six months ended in Jan. 2024 was $ -7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2024 was $-11 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sigma Healthcare's Operating Income for the six months ended in Jan. 2024 was $ 9 Mil. Sigma Healthcare's Interest Expense for the six months ended in Jan. 2024 was $ -7 Mil. Sigma Healthcare's Interest Coverage for the quarter that ended in Jan. 2024 was 1.19. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sigma Healthcare Interest Expense Historical Data

The historical data trend for Sigma Healthcare's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigma Healthcare Interest Expense Chart

Sigma Healthcare Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Interest Expense

Get a 7-Day Free Trial

-9.21

-9.14

-7.78

-10.02

-10.82

Sigma Healthcare Semi-Annual Data
	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jul19	Jan20	Jul20	Jan21	Jul21	Jan22	Jul22	Jan23	Jul23	Jan24
Interest Expense	Get a 7-Day Free Trial															-6.41	-2.17	-7.82	-3.72	-7.16

Sigma Healthcare Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-11 Mil.

Sigma Healthcare (OTCPK:SIGGF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sigma Healthcare's Interest Expense for the six months ended in Jan. 2024 was $-7 Mil. Its Operating Income for the six months ended in Jan. 2024 was $9 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jan. 2024 was $84 Mil.

Sigma Healthcare's Interest Coverage for the quarter that ended in Jan. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jan. 2024 )	/	Interest Expense (Q: Jan. 2024 )
	=	-1	*	8.531	/	-7.161
	=	1.19

The higher the ratio, the stronger the company's financial strength is.

Sigma Healthcare (Sigma Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sigma Healthcare Ltd (OTCPK:SIGGF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

S5YA:Germany SIG:Australia

Address

2125 Dandenong Road, Level 6, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.sigmahealthcare.com.au

Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.